CURRENT APPROACHES TO THE DIAGNOSIS AND TREATMENT OF BREAST CANCER PATIENTS
DOI:
https://doi.org/10.32471/oncology.2663-7928.t-23-1-2021-g.9320Keywords:
breast cancer, diagnosis, heterogeneity, micro-RNA, personalized treatmentAbstract
The review presents current data on the diagnosis and treatment of the patients with primary operable breast cancer and focuses on the development of personalized approaches to the treatment strategy of this common disease. In the article, the authors present the results of clinical studies which confirmed the role of determining miRNAs expression not only for timely and complete but also for personalized treatment of patients. The marked heterogeneity of breast cancer and subtypes of the disease based on clinical, morphological, molecular, genetic, epidemiological and other approaches, as well as significant differences in risk factors suggest that the treatment strategy of patients with breast cancer has not been completely resolved. Nevertheless, the current level of knowledge about the molecular mechanisms of breast cancer origin and development, its sensitivity or resistance to various drugs and treatment modalities allows us to start the transition from averaged standard treatment regimens to treatment based on individual patient particularities and biological characteristics of the tumor. Moreover, deepening our knowledge of breast cancer biology could become a key to understanding local recurrence and distant metastases development after the radical treatment.
References
Konat-Bąska K, Matkowski R, Błaszczyk J, et al. Does breast cancer increasingly affect younger women? Int J Environ Res Public Health 2020; 17 (13): 4884 (https://www.mdpi.com/1660–4601/17/13/4884).
Maisonneuve P, Disalvatore D, Rotmensz N, et al. Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypes. Breast Cancer Res 2014; 16 (3): R65 (https://breast-cancer-research.biomedcentral.com/articles/10.1186/bcr3679).
Polyak K. Heterogeneity in breast cancer. J Clin Invest 2011; 121 (10): 3786–88.
Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406 (6797): 747–52.
Hayes DF, Isaacs C, Stearns V. Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia 2001; 6 (4): 375–392.
Guidroz JA, Scott-Conner CEH, Weiget RJ. Management of pregnant women with breast cancer. J Surg Oncol 2011; 103 (4): 337–40.
Bullier B, MacGrogan G, Bonnefoi H, et al. Imaging features of sporadic breast cancer in women under 40 years old. Eur Radiol 2013; 23 (12): 3237–45.
Olivas-Maguregui S, Villasenor-Navarro Y, Ferrari-Carballo T, et al. Importance of the preoperative evaluation of multifocal and multicentric breast cancer with magnetic resonance imaging in women with dense parenchyma. Rev Invest Clin 2008; 60 (5): 382–9.
Corradini S, Reitz D, Pazos M, et al. Mastectomy or breast-conserving therapy for early breast cancer in real-life clinical practice: outcome comparison of 7565 cases. Cancers 2019; 1 1(2): 160 (https://www.mdpi.com/2072–6694/11/2/160).
Pallone MJ, Poplack SP, Barth RJ, et al. Combining supine MRI and 3D optical scanning for improved surgical planning of breast conserving sugeries. Proceedings of the SPIE 2012; 8316: id. 83163B (DOI: 10.1117/12.912803)
Soares F, Janela F, Pereira M, et al. 3D lacunarity in multifractal analysis of breast tumor lesions in dynamic contrast-enhanced magnetic resonance imaging. IEEE Trans Image Process 2013; 22(11–12): 4422–35.
Schilling K, Narayanan D, Kalinyak JE, et al. Positron emission mammography in breast cancer presurgical planning: comparisons with magnetic resonance imaging. Eur J Nucl Med Mol Imag 2011; 38 (1): 23–6.
Fann JC-Y, Chang K-J, Hsu C-Y, et al. Impact of overdiagnosis on long-term breast cancer survival. Cancers 2019; 11: 325 (https://www.mdpi.com/2072–6694/11/3/325).
Ogbuanya AU, Anyanwu SN, Iyare EF, et al. The role of fine needle aspiration cytology in triple assessment of patients with malignant breast lumps. Niger J Surg 2020; 26 (1): 35–41.
Cui X, Schiff R, Arpino G, et al. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy. J Clin Oncol 2005; 23 (30): 7721–35.
Rakha EA, El-Sayed ME, Green AR, et al. Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype. J Clin Oncol 2007; 25 (30): 4772–78.
Gonçalves A, Sabatier R, Charafe-Jauffret E, et al. Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives. Bull Cancer 2013; 100 (5): 453–64.
Marcom PK, Isaacs C, Harris L, et al. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 2007; 102 (1): 43–9.
Creighton CJ, Kent Osborne C, van de Vijver MJ, et al. Molecular profiles of progesterone receptor loss in human breast tumors. Breast Cancer Res Treat 2009; 114: 287–99.
Bose S. Triple-negative breast carcinoma: morphologic and molecular subtypes. Аdv Anat Pathol 2015; 22 (5): 306–13.
Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Int J Cancer 2012; 131 (11): 2471–77.
Wang J, Zhang K-Y, Liu S-M, et al. Tumor-associated circulating microRNAs as biomarkers of cancer. Molecules 2014; 19 (2): 1912–38.
Iwakawa H-O, Tomari Y. The functions of microRNAs: mRNA decay and translational repression. Trends in Cell Biol 2015; 25 (11): 651–65.
John B, Enright AJ, Aravin A, et al. Human microRNA targets. PLoS Biol 2004; 2 (11): e363.
Rajewsky N. microRNA target predictions in animals. Nat Genet 2006; 38(6): S8–S13.
Friedman RC. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19 (1): 92–105.
Lu J, Getz G, Miska EA, et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435 (7043): 834–38.
Zaravinos A. The regulatory role of microRNAs in EMT and cancer. J Oncol 2015; 2015: 865816.
Eissa S, Matboli M, Shehata HH, et al. MicroRNA-10b and minichromosome maintenance complex component 5 gene as prognostic biomarkers in breast cancer. Tumor Biol 2015; 36 (6): 4487–94.
Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449 (7163): 682–88.
Abdulhussain MM, Hasan NA, Hussain AG. Interrelation of the circulating and tissue MicroRNA-21 with tissue PDCD4 expression and the invasiveness of Iraqi female breast tumors. Indian J Clin Biochem 2019; 34 (1): 26–38.
Zheng SR, Guo GL, Zhai Q, et al. Effects of miR-155 antisense oligonucleotide on breast carcinoma cell line MDA-MB-157 and implanted tumors. Asian Pac J Cancer Prev 2013; 14 (4): 2361–66.
Zhang CM, Zhao J, Deng HY. MiR-155 promotes proliferation of human breast cancer MCF-7 cells through targeting tumor protein 53-induced nuclear protein 1. J Biomed Sci 2013; 20 (1): 1–10.
Yu SJ, Hu JY, Kuang XY, et al. MicroRNA-200a promotes anoikis resistance and metastasis by targeting YAP1 in human breast cancer. Clin Cancer Res 2013; 19 (6): 1389–99.
Wang Y, Rathinam R, Walch A, et al. ST14 (Suppression of tumorigenicity 14) gene is a target for miR-27b, and the inhibitory effect of ST14 on cell growth is independent of miR-27b regulation. J Biol Chem 2009; 284 (34): 23094–106.
Zhang L, Du Y, Xu S, et al. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. Cancer Lett 2019; 442: 242–51.
Li J, Li X, Kong X, et al. MiRNA-26b inhibits cellular proliferation by targeting CDK8 in breast cancer. Int J Clin Exp Med 2014; 7 (3): 558–65.
Ma X, Dong W, Su Z, et al. Functional roles of sialylation in breast cancer progression through miR-26a/26b targeting ST8SIA4. Cell Death Dis 2016; 7 (12): e2561–e2561.
Yan G, Li Y, Zhan L, et al. Decreased miR-124–3p promoted breast cancer proliferation and metastasis by targeting MGAT5. Am J Cancer Res 2019; 9 (3): 585–96.
Seo S, Moon Y, Choi J, et al. The GTP binding activity of transglutaminase 2 promotes bone metastasis of breast cancer cells by downregulating microRNA-205. Am J Cancer Res 2019; 9 (3): 597–607.
Wang L, Kang FB, Wang J, et al. Downregulation of miR-205 contributes to epithelial-mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1-RAGE signaling pathway. Anti-Cancer Drugs 2019; 30 (3): 225–32.
Lo TF, Tsai WC, Chen ST. MicroRNA-21–3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growth. PLoS One 2013; 8 (9): e75628.
Lo SN, Wang CW, Chen YS, et al. Berberine activates aryl hydrocarbon receptor but suppresses CYP1A1 induction through miR-21–3p stimulation in MCF-7 breast cancer cells. Molecules 2017; 22 (11): 1847 (https://www.mdpi.com/1420–3049/22/11/1847).
Lin C, Gao B, Yan X, et al. MicroRNA 628 suppresses migration and invasion of breast cancer stem cells through targeting SOS1. Onco Targets Ther 2018; 11: 5419–28.
Khalighfard S. Plasma miR-21, miR-155, miR-10b, and Let-7a as the potential biomarkers for the monitoring of breast cancer patients. Sci Rep 2018; 8 (1): 1–11.
Shi J. Considering exosomal miR-21 as a biomarker for cancer. J Clin Med 2016; 5 (4): 42 (https://www.mdpi.com/2077–0383/5/4/42).
Eichelser C, Stückrath I, Müller V, et al. Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget 2014; 5 (20): 9650–63.
Fortis SP, Vaxevanis CK, Mahaira LG, et al. Serum miRNA-based distinct clusters define three groups of breast cancer patients with different clinicopathological and immune characteristics. Cancer Immunol Immunother 2019; 68 (1): 57–70.
Mishra S, Srivastava AK, Suman S, et al. Circulating miRNAs revealed as surrogate molecular signatures for the early detection of breast cancer. Cancer Lett 2015; 369 (1): 67–75.
Masuda T, Shinden Y, Noda M, et al. Circulating pre-microRNA-488 in peripheral blood is a potential biomarker for predicting recurrence in breast cancer. Anticancer Res 2018; 38 (8): 4515–23.
Liu B, Su F, Chen M, et al. Serum miR-21 and miR-125b as markers predicting neoadjuvant chemotherapy response and prognosis in stage II/III breast cancer. Human Pathol 2017; 64: 44–52.
Dooley WC. Surgery for breast cancer. Curr Opin Oncol 1998; 10 (6): 504–12.
Wyld L, Audisio RA, Poston GJ. The evolution of cancer surgery and future perspectives. Nat Rev Clin Oncol 2015; 12 (2): 115–24.
Cattelani L, Polotto S, Arcuri MF, et al. One-step prepectoral breast reconstruction with dermal matrix-covered implant compared to submuscular implantation: functional and cost evaluation. Clin Breast Cancer 2018; 18 (4): e703–e711.
Riis M. Modern surgical treatment of breast cancer. Ann Med Surg (Lond) 2020; 56: 95–107.
Tosello G, Torloni MR, Mota BS, et al. Breast surgery for metastatic breast cancer. Cochrane Database Syst Rev 2018; 3 (3): CD011276 (https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD011276.pub2/full).
Cheung KL. Treatment strategies and survival outcomes in breast cancer. Cancers (Basel) 2020; 12 (3): 735 (https://www.mdpi.com/2072–6694/12/3/735/htm).
Salibian AA, Frey JD, Karp NS. Strategies and considerations in selecting between subpectoral and prepectoral breast reconstruction. Gland Surg 2019; 8 (1): 11–18.
Brown M, Namnoum JD. Indications and controversies for implant-only based breast reconstruction. Clin Plast Surg 2018; 45 (1): 47–54.
Waks AG, Winer EP. Breast cancer treatment: a review. JAMA 2019; 321 (3): 288–300.
Moo TA, Sanford R, Dang C, et al. Overview of breast cancer therapy. PET Clin 2018; 13 (3): 339–54.
Weber WP, Soysal SD, El-Tamer M, et al. First international consensus conference on standardization of oncoplastic breast conserving surgery. Breast Cancer Res Treat 2017; 165 (1): 139–49.
Rubio IT, Wyld L, Esgueva A, et al. Variability in breast cancer surgery training across Europe: an ESSO-EUSOMA international survey. Eur J Surg Oncol 2019; 45 (4): 567–72.
Nounou MI, El Amrawy F, Ahmed N, et al. Breast cancer: conventional diagnosis and treatment modalities and recent patents and technologies. Breast Cancer (Auckl) 2015; 9 (Suppl 2): 17–34.
Murphy BD, Kerrebijn I, Farhadi J, et al. Indications and controversies for abdominally-based complete autologous tissue breast reconstruction. Clin Plast Surg 2018; 45 (1): 83–91.
Walker DK, Whitehead L. Breast surgery for metastatic breast cancer. Br J Community Nurs 2018; 23 (7): 334–35.
Lanitis S, Tekkis PP, Sgourakis G, et al. Comparison of skin-sparing mastectomy versus non-skin-sparing mastectomy for breast cancer: a meta-analysis of observational studies. Ann Surg 2010; 251 (4): 632–39.
De La Cruz L, Moody AM, Tappy EE, et al. Overall survival, disease-free survival, local recurrence, and nipple-areolar recurrence in the setting of nipple-sparing mastectomy: a meta-analysis and systematic review. Ann Surg Oncol 2015; 22 (10): 3241–49.
Lewis L, Cox J, Morgia M, et al. A clip-based protocol for breast boost radiotherapy provides clear target visualisation and demonstrates significant volume reduction over time. J Med Radiat Sci 2015; 62: 177–83.
Winzer KJ, Sauerbrei W, Braun M, et al. Radiation therapy and tamoxifen after breast-conserving surgery: updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence. Eur J Cancer 2010; 46 (1): 95–101.
Hlavka A, Vanasek J, Odrazka K, et al. Tumor bed radiotherapy in women following breast conserving surgery for breast cancer-safety margin with/without image guidance. Oncol Lett 2018; 15: 6009–14.
Matuschek C, Bölke E, Haussmann J, et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat Oncol 2017; 12 (1): 60 (https://ro-journal.biomedcentral.com/articles/10.1186/s13014–017–0796-x).
Onitilo AA, Engel JM, Stankowski RV, et al. Survival comparisons for breast conserving surgery and mastectomy revisited: community experience and the role of radiation therapy. Clin Med Res 2015; 13: 65–73.
Land LH, Dalton SO, Jensen MB, et al. Influence of comorbidity on the effect of adjuvant treatment and age in patients with early-stage breast cancer. Br J Cancer 2012; 107 (11): 1901–07.
Tann AW, Hatch SS, Joyner MM, et al. Accelerated partial breast irradiation: Past, present, and future. World J Clin Oncol 2016; 7 (5): 370–9.
Koerkamp GML, Vasmel JE, Russell NS, et al. Optimizing MR-guided radiotherapy for breast cancer patients. Front Oncol 2020; 10: 1107 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7399349/).
Lalani N, Voduc KD, Jimenez RB, et al. Breast cancer molecular subtype as a predictor of radiation therapy fractionation sensitivity. Int J Radiat Oncol Biol Phys 2021; 109 (1): 281–7.
Kayali M, Abi Jaoude J, Tfayli A, et al. Post-mastectomy radiation therapy in breast cancer patients with 1–3 positive lymph nodes: No one size fits all. Crit Rev Oncol Hematol 2020; 147: 102880 (https://www.sciencedirect.com/science/article/abs/pii/S1040842820300184).
Bergh J, Jönsson PE, Glimelius B, et al. Swedish council of technology assessment in health care. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40 (2–3): 253–81.
Hussain SA, Palmer DH, Stevens A, et al. Role of chemotherapy in breast cancer. Expert Rev Anticancer Ther 2005; 5 (6): 1095–110.
Du XL, Jones DV, Zhang D. Effectiveness of adjuvant chemotherapy for node-positive operable breast cancer in older women. J Gerontol A Biol Sci Med Sci 2005; 60 (9): 1137–44.
Hassan MS, Ansari J, Spooner D, et al. Chemotherapy for breast cancer (Review). Oncol Rep 2010; 24 (5): 1121–31.
Swain SM. Chemotherapy: updates and new perspectives. Oncologist 2011; 16 (Suppl 1): 30–39.
Hennigs A, Riedel F, Marmé F, et al. Changes in chemotherapy usage and outcome of early breast cancer patients in the last decade. Breast Cancer Res Treat 2016; 160(3): 491–99.
Zarcos-Pedrinaci I, Redondo M, Louro J, et al. Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. Cancer Med 2019; 8 (15): 6662–70.
Cheung KL. Treatment strategies and survival outcomes in breast cancer. Cancers (Basel) 2020; 12 (3): 735 (https://www.mdpi.com/2072–6694/12/3/735/htm).
Haidinger R, Bauerfeind I. Long-term side effects of adjuvant therapy in primary breast cancer patients: results of a web-based survey. Breast Care (Basel) 2019; 14 (2): 111–16.
El Hachem G, Gombos A, Awada A. Recent advances in understanding breast cancer and emerging therapies with a focus on luminal and triple-negative breast cancer. F1000Res 2019; 8: F1000 Faculty Rev-591.
Mehanna J, Haddad FG, Eid R, et al. Triple-negative breast cancer: current perspective on the evolving therapeutic landscape. Int J Womens Health 2019; 11: 431–37.
Berkowitz MJ, Thompson CK, Zibecchi LT, et al. How patients experience endocrine therapy for breast cancer: an online survey of side effects, adherence, and medical team support. J Cancer Surviv 2020; 2020: 1–11.
Walsh EM, Smith KL, Stearns V. Management of hormone receptor-positive, HER2-negative early breast cancer. Semin Oncol 2020; 47 (4): 187–200.
Aiello Bowles EJ, Boudreau DM, Chubak J, et al. Patient-reported discontinuation of endocrine therapy and related adverse effects among women with early-stage breast cancer. J Oncol Pract 2012; 8: e149–57.
Jerevall PL, Ma XJ, Li H, et al. Prognostic utility of HOXB13:IL17BR and molecular grade index in early-stage breast cancer patients from the Stockholm trial. Br J Cancer 2011; 104: 1762–69.
Goldhirsch A, Wood WC, Coates AS. Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy for early breast cancer. Ann Oncol 2011; 22: 1736–47.
Abdulkareem IH, Zurmi IB. Review of hormonal treatment of breast cancer. Niger J Clin Pract 2012; 15 (1): 9–14.
Thurlimann B, Price KN, Gelber RD. Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11–93. Breast Cancer Res Treat 2009; 113: 137–44.
Higgins MJ, Stearns V. Pharmacogenetics of endocrine therapy for breast cancer. Annu Rev Med 2011; 62; 281–293.
Dembinski R, Prasath V, Bohnak C, et al. Estrogen receptor positive and progesterone receptor negative breast cancer: the role of hormone therapy. Horm Cancer 2020; 11 (3–4):148–154.
Rauh C, Schuetz F, Rack B, et al. Hormone therapy and its effect on the prognosis in breast cancer patients. Geburtshilfe Frauenheilkd 2015; 75 (6): 588–96.
Drăgănescu M, Carmocan C. Hormone Therapy in breast cancer. Chirurgia (Bucur) 2017; 112 (4): 413–17.
Puhalla S, Bhattacharya S, Davidson NE. Hormonal therapy in breast cancer: a model disease for the personalization of cancer care. Mol Oncol 2012; 6 (2): 222–36.
Awan A, Esfahani K. Endocrine therapy for breast cancer in the primary care setting. Curr Oncol 2018; 25 (4): 285–91.
Shen LS, Jin XY, Wang XM, et al. Advances in endocrine and targeted therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer. Chin Med J (Engl) 2020; 133 (9): 1099–08.
Kreutzfeldt J, Rozeboom B, Dey N, et al. The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. Am J Cancer Res 2020; 10 (4): 1045–67.
Mazzotta M, Krasniqi E, Barchiesi G, et al. Long-term safety and real-world effectiveness of trastuzumab in breast cancer. J Clin Med 2019; 8 (2): 254 (https://www.mdpi.com/2077–0383/8/2/254).
Maximiano S, Magalhães P, Guerreiro MP, et al. Trastuzumab in the Treatment of Breast Cancer. BioDrugs 2016; 30 (2): 75–86.
Pinto AC, Ades F, de Azambuja E, et al. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies. Breast 2013; 22 (Suppl 2): S152–5.
González-Santiago S, Saura C, Ciruelos E, et al. Real-world effectiveness of dual HER2 blockade with pertuzumab and trastuzumab for neoadjuvant treatment of HER2-positive early breast cancer (The NEOPETRA Study). Breast Cancer Res Treat 2020; 184 (2): 469–479.
Zagouri F, Sergentanis TN, Chrysikos D, et al. Pertuzumab in breast cancer: a systematic review. Clin Breast Cancer 2013; 13 (5): 315–24.
Tookman L, Roylance R. New drugs for breast cancer. Brit Med Bull 2010; 96: 111–29.
Wilson FR, Coombes ME, Wylie Q, et al. Herceptin® (trastuzumab) in HER2-positive early breast cancer: protocol for a systematic review and cumulative network meta-analysis. Syst Rev 2017; 6 (1): 196 (https://link.springer.com/article/10.1186/s13643–017–0588–2).
Martin AP, Downing J, Cochrane M, et al. Trastuzumab uptake in HER2-positive breast cancer patients: a systematic review and meta-analysis of observational studies. Crit Rev Oncol Hematol 2018; 130: 92–107.
Xie Y, Ge R, Sang D, et al. Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: a multicenter, retrospective study. Cancer Med 2020; 9 (9): 2981–88.
Ye X, Luo X, Du Q, et al. Efficacy and safety of lapatinib in Chinese breast cancer patients: a real-world study. Ann Transl Med 2020; 8(5): 240 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154472/).
Du L, Li X, Zhen L, et al. Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway. Mol Med Rep 2018; 17 (5): 7163–69.
Raphael J, Lefebvre C, Allan A, et al. everolimus in advanced breast cancer: a systematic review and meta-analysis. Target Oncol 2020; 15 (6): 723–32.
Sharma M, Duan Z, Zhao H, et al. Real-world patterns of everolimus use in patients with metastatic breast cancer. Oncologist 2020; 25 (11): 937–42.
Krug D, Baumann R, Budach W, et al. Current controversies in radiotherapy for breast cancer. Radiat Oncol 2017; 12 (1): 25 (https://link.springer.com/article/10.1186/s13014–017–0766–3).
Harashchenko O, Antonov V, Konovalenko V. Support tool for decision making in selecting chemotherapy tactics for trearment of breast cancer parients. G Med News. 2019; 6 (291): 20–25.
Manoj Gowda S, Kabeer KK, Jafferbhoy S, et al. Breast cancer management guidelines during COVID-19 pandemic. Indian J Surg 2020; 1–8.
Tasoulis MK, Roche N, MacNeill F. Rationalizing breast cancer surgery during the COVID-19 pandemic. Eur J Surg Oncol 2020; 46 (6): 1192–93.
